Medicalgorithmics Receives FDA Approval for Commercialization of New Arrhythmia Diagnostics Platform in the USA
The U.S. Food and Drug Administration (FDA) – a federal agency overseeing the market for drugs and medical devices – has approved Medicalgorithmics’ new cloud-based platform for arrhythmia diagnostics, the DeepRhythm Platform (DRP), for use in the USA. The platform integrates with the latest generation of proprietary artificial intelligence algorithms, DRAI. FDA approval allows for the commercial deployment of this new solution to clients in the U.S. market. This decision positions the company’s product offering among the world’s leading solutions, opens up new business opportunities, and enhances its competitive and technological edge in the arrhythmia diagnostics market.